Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2011 1
2012 1
2013 2
2014 1
2015 1
2016 2
2017 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.
Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, Wu K, Akutagawa J, Bridges O, Marino R, Wohlfeil M, Braun BS, Mullighan CG, Loh ML. Diaz-Flores E, et al. Among authors: akutagawa j. Cancer Res. 2019 May 1;79(9):2339-2351. doi: 10.1158/0008-5472.CAN-18-0236. Epub 2019 Mar 12. Cancer Res. 2019. PMID: 30862722 Free PMC article.
The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML. Tran TH, et al. Among authors: akutagawa j. Haematologica. 2021 Aug 1;106(8):2242-2245. doi: 10.3324/haematol.2020.261354. Haematologica. 2021. PMID: 33626861 Free PMC article. No abstract available.
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML. Stieglitz E, et al. Among authors: akutagawa j. Blood. 2015 Jan 15;125(3):516-24. doi: 10.1182/blood-2014-09-601690. Epub 2014 Nov 13. Blood. 2015. PMID: 25395418 Free PMC article.
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Akutagawa J, Huang TQ, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman LS, Sampath D, Braun BS. Akutagawa J, et al. Leukemia. 2016 Jun;30(6):1335-43. doi: 10.1038/leu.2016.14. Epub 2016 Feb 12. Leukemia. 2016. PMID: 26965285 Free PMC article.
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Chang T, et al. Among authors: akutagawa j. J Clin Invest. 2016 Jan;126(1):404. doi: 10.1172/JCI85325. Epub 2016 Jan 4. J Clin Invest. 2016. PMID: 26727232 Free PMC article. No abstract available.
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS. Lyubynska N, et al. Among authors: akutagawa jk. Sci Transl Med. 2011 Mar 30;3(76):76ra27. doi: 10.1126/scitranslmed.3001069. Sci Transl Med. 2011. PMID: 21451123 Free PMC article.
11 results